stockrow
Saturday 7 November 2026
Export SCNI’s income statement to Excel — free account
Scinai Immunotherapeutics Ltd. Sponsored ADR
SCNI Healthcare Biotechnology
Scinai Immunotherapeutics Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 million, up 99.2% from fiscal 2024.
- EPS
- −85.8%
- Free cash flow
- +51.1%
Quarter to June 2026, against a year earlier
0.44
0.01
−2.22%
Follow SCNI
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 1 | 1 | — | +99.2% | — | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | (88.15) | (202.29) | 0.00 | (202.3) pt | ||||||
| EBT | (2) | (10) | (23) | (32) | (1) | (8) | (6) | (6) | 5 | (8) | 10 | +14.9% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 728.88 | (633.64) | 0.00 | (633.6) pt | ||||||
| Net income | (2) | (10) | (23) | (32) | (1) | (8) | (6) | (6) | 5 | (8) | (1) | +14.9% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.16 | 5.61 | 0.00 | n/m | |||||
| Earnings | (707.34) | (1,980.00) | (3,600.00) | (3,600.00) | (120.00) | (581.57) | (307.48) | (166.39) | 59.50 | (35.60) | 85.26 | (28.3%) | ||||||
| Cash flow | (743.46) | (579.80) | (2,347.85) | (2,719.15) | (2,032.61) | (526.67) | (384.39) | (240.16) | (78.56) | (25.83) | 0.00 | (31.2%) | ||||||
| Capex | (1.48) | (260.00) | (968.46) | (262.20) | (167.30) | (9.86) | (44.23) | (16.31) | (0.15) | (0.10) | 0.00 | (25.6%) | ||||||
| Free cash flow | (744.94) | (839.80) | (3,316.31) | (2,981.34) | (2,199.91) | (536.52) | (428.62) | (256.47) | (78.71) | (25.93) | 0.00 | (31.1%) | ||||||
| Book value | 1,972.50 | 3,245.00 | (1,281.23) | (2,295.49) | (409.01) | 69.65 | (93.12) | (116.96) | 123.73 | 34.70 | 0.00 | (36.2%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +60.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.85 | 0.05 | 0.01 | 0.5 | |||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| P/B | — | — | — | — | — | — | — | — | 0.65 | 0.56 | 0.03 | 0.6 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | (0.22) | (0.01) | 0.32 | (0.1) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (3) | (3) | (15) | (22) | (23) | (7) | (7) | (9) | (6) | (6) | (6) | +10.2% | |||||
| Capex | 0 | (1) | (6) | (2) | (2) | 0 | (1) | (1) | 0 | 0 | 0 | +19.0% | ||||||
| Free cash flow | (3) | (4) | (22) | (24) | (24) | (8) | (8) | (10) | (6) | (6) | (7) | +10.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 6 | 20 | 15 | 16 | (17) | 15 | 12 | 4 | 1 | 0 | 1 | (25.3%) | |||||
| Net debt | (7) | (21) | 5 | 15 | 18 | 10 | 6 | 14 | (2) | (2) | (3) | (15.1%) | ||||||
| Shareholders’ equity | 7 | 16 | (8) | (19) | (5) | 1 | (2) | (5) | 10 | 8 | 12 | +2.2% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (25.94) | (63.49) | (90.37) | (102.37) | (5.41) | (33.00) | (19.61) | (29.19) | 31.02 | (66.26) | 0.00 | (40.3) pt | |||||
| ROIC | (2,545.23) | 0.00 | 0.00 | 0.00 | 10.79 | (63.87) | (168.33) | (61.97) | (66.31) | (71.57) | 0.00 | +2,473.7 pt | ||||||
| ROE | (31.31) | (87.09) | (592.81) | 232.74 | 11.86 | 461.27 | 1,489.97 | 205.40 | (4,379.91) | (243.39) | 0.00 | (212.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 14 | 14 | 21 | 25 | 21 | 15 | 33 | 31 | 31 | 45 | — | +13.9% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Mar 2026 · fundamentals updated 26 Oct 2026
Scinai Immunotherapeutics Ltd. Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SPRC SciSparc Ltd. | $880.0K | — (loss-making) | 7.9× | — | n/m | +14.95% (above 0%: growing) | 35.75% | 0.00% | Compare |
| LNAI Lunai Bioworks Inc. | $830.0K | — (loss-making) | — | — | n/m | −1.65% (below 0%: shrinking) | 100.00% | (6,877.49%) | Compare |
| ATXI Avenue Therapeutics, Inc. | $680.0K | — (loss-making) | — (loss-making) | — | n/m | −169.89% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MLEC Moolec Science SA | $620.0K | — (loss-making) | — (loss-making) | +948.39% (above 0%: growing) | n/m | +4.48% (above 0%: growing) | (25.52%) | (77.92%) | Compare |
| CDT CDT Equity Inc. | $390.0K | — (loss-making) | — | — | n/m | +78.92% (above 0%: growing) | — | 0.00% | Compare |
| SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR | $320.0K | 0.0× | — (loss-making) | — | −85.80% (below 0%: shrinking) | +51.13% (above 0%: growing) | (228.63%) | (504.50%) | |
| VINC Vincerx Pharma, Inc. | $250.0K | — (loss-making) | — | — | n/m | +42.45% (above 0%: growing) | 0.00% | 0.00% | Compare |
| VRPX Virpax Pharmaceuticals, Inc. | $160.0K | — (loss-making) | — | — | n/m | +4.68% (above 0%: growing) | — | 0.00% | Compare |
| CERO CERo Therapeutics Holdings, Inc. | $140.0K | — (loss-making) | — | — | n/m | +49.65% (above 0%: growing) | — | 0.00% | Compare |
| Median of peers | $505.0K | — | — | — | — | +9.82% | 35.75% | 0.00% |